SG10201906517VA - Synthesis of a bruton's tyrosine kinase inhibitor - Google Patents
Synthesis of a bruton's tyrosine kinase inhibitorInfo
- Publication number
- SG10201906517VA SG10201906517VA SG10201906517VA SG10201906517VA SG10201906517VA SG 10201906517V A SG10201906517V A SG 10201906517VA SG 10201906517V A SG10201906517V A SG 10201906517VA SG 10201906517V A SG10201906517V A SG 10201906517VA SG 10201906517V A SG10201906517V A SG 10201906517VA
- Authority
- SG
- Singapore
- Prior art keywords
- bruton
- synthesis
- tyrosine kinase
- kinase inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103507P | 2015-01-14 | 2015-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201906517VA true SG10201906517VA (en) | 2019-08-27 |
Family
ID=56406389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705678YA SG11201705678YA (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
| SG10201906517VA SG10201906517VA (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705678YA SG11201705678YA (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20180009814A1 (fr) |
| EP (1) | EP3245208A4 (fr) |
| JP (2) | JP2018502077A (fr) |
| KR (1) | KR20170102887A (fr) |
| CN (2) | CN113816962A (fr) |
| AU (2) | AU2016206693A1 (fr) |
| BR (1) | BR112017015206B1 (fr) |
| CA (2) | CA2971460C (fr) |
| HK (1) | HK1246293A1 (fr) |
| IL (3) | IL308276A (fr) |
| MA (1) | MA41350A (fr) |
| MX (2) | MX366827B (fr) |
| RU (1) | RU2017128308A (fr) |
| SG (2) | SG11201705678YA (fr) |
| WO (1) | WO2016115356A1 (fr) |
| ZA (1) | ZA201704338B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3257855B1 (fr) * | 2015-02-12 | 2020-04-22 | Shanghai Dude Medical Science and Technology Co., Ltd. | Procédé de préparation d'ibrutinib |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (fr) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | Préparation et composition de traitement de tumeurs malignes |
| CN109206426B (zh) * | 2017-07-06 | 2021-10-08 | 上海复星星泰医药科技有限公司 | 吡唑并嘧啶类化合物的制备方法 |
| US20200369611A1 (en) | 2017-08-01 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Intermediate compounds and methods |
| CN107814804A (zh) * | 2017-10-27 | 2018-03-20 | 广州科锐特生物科技有限公司 | 依鲁替尼的制备方法 |
| WO2019181876A1 (fr) | 2018-03-19 | 2019-09-26 | 大鵬薬品工業株式会社 | Composition pharmaceutique comprenant du sulfate d'alkyle de sodium |
| EP3787751A1 (fr) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Polythérapie d'une thérapie par lymphocytes t à récepteur antigénique chimérique (car) et d'un inhibiteur de btk |
| JP6944496B2 (ja) * | 2018-10-22 | 2021-10-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
| WO2020095452A1 (fr) | 2018-11-09 | 2020-05-14 | 大鵬薬品工業株式会社 | Procédé de fabrication de composé diméthoxybenzène |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| BR112021022646A2 (pt) | 2019-05-21 | 2022-03-29 | Janssen Pharmaceutica Nv | Processos e intermediários para a preparação de um inibidor de btk |
| KR20220011668A (ko) | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
| US20240092785A1 (en) | 2021-01-21 | 2024-03-21 | Synthon B.V. | Process for making ibrutinib |
| CN114853662B (zh) * | 2021-02-05 | 2024-01-12 | 四川青木制药有限公司 | 手性肼基哌啶衍生物的制备方法 |
| WO2023220655A1 (fr) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t |
| WO2023242384A1 (fr) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Formes cristallines d'ibrutinib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
| US4874822A (en) * | 1988-04-07 | 1989-10-17 | Minnesota Mining And Manufacturing Company | Process for the acrylamidoacylation of alcohols |
| PL1706385T3 (pl) * | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
| EP2526933B1 (fr) * | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibiteurs de la tyrosine kinase de Bruton |
| SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| AU2013296627C9 (en) * | 2012-07-30 | 2018-03-22 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| CN105471823B (zh) * | 2014-09-03 | 2018-10-26 | 阿里巴巴集团控股有限公司 | 一种敏感信息处理方法、装置、服务器及安全判定*** |
| WO2016115869A1 (fr) * | 2015-01-21 | 2016-07-28 | 中国科学院合肥物质科学研究院 | Nouvel inhibiteur de la kinase flt3 et utilisation de ce dernier |
-
2016
- 2016-01-13 MA MA041350A patent/MA41350A/fr unknown
- 2016-01-14 CA CA2971460A patent/CA2971460C/fr active Active
- 2016-01-14 WO PCT/US2016/013424 patent/WO2016115356A1/fr active Application Filing
- 2016-01-14 RU RU2017128308A patent/RU2017128308A/ru not_active Application Discontinuation
- 2016-01-14 BR BR112017015206-1A patent/BR112017015206B1/pt active IP Right Grant
- 2016-01-14 CN CN202110485400.6A patent/CN113816962A/zh active Pending
- 2016-01-14 AU AU2016206693A patent/AU2016206693A1/en not_active Abandoned
- 2016-01-14 SG SG11201705678YA patent/SG11201705678YA/en unknown
- 2016-01-14 US US15/542,848 patent/US20180009814A1/en not_active Abandoned
- 2016-01-14 SG SG10201906517VA patent/SG10201906517VA/en unknown
- 2016-01-14 CN CN201680005456.4A patent/CN107108640A/zh active Pending
- 2016-01-14 CA CA3210320A patent/CA3210320A1/fr active Pending
- 2016-01-14 JP JP2017532649A patent/JP2018502077A/ja active Pending
- 2016-01-14 KR KR1020177019206A patent/KR20170102887A/ko not_active Application Discontinuation
- 2016-01-14 EP EP16737886.8A patent/EP3245208A4/fr not_active Withdrawn
- 2016-01-14 IL IL308276A patent/IL308276A/en unknown
- 2016-01-14 MX MX2017009154A patent/MX366827B/es active IP Right Grant
-
2017
- 2017-06-19 IL IL253020A patent/IL253020A0/en unknown
- 2017-06-26 ZA ZA2017/04338A patent/ZA201704338B/en unknown
- 2017-07-12 MX MX2019008815A patent/MX2019008815A/es unknown
-
2018
- 2018-05-07 HK HK18105861.5A patent/HK1246293A1/zh unknown
- 2018-12-18 US US16/224,425 patent/US20190367518A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/703,344 patent/US20200347064A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274716A patent/IL274716A/en unknown
- 2020-09-11 AU AU2020230323A patent/AU2020230323A1/en not_active Abandoned
- 2020-10-09 JP JP2020171454A patent/JP2021035947A/ja active Pending
-
2021
- 2021-02-17 US US17/177,852 patent/US20220098200A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/209,939 patent/US20240158400A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201705678YA (en) | 2017-08-30 |
| IL253020A0 (en) | 2017-08-31 |
| IL308276A (en) | 2024-01-01 |
| MX2017009154A (es) | 2017-10-12 |
| CA2971460C (fr) | 2023-10-10 |
| CN107108640A (zh) | 2017-08-29 |
| JP2018502077A (ja) | 2018-01-25 |
| CA3210320A1 (fr) | 2016-07-21 |
| MX2019008815A (es) | 2019-09-26 |
| HK1246293A1 (zh) | 2018-09-07 |
| ZA201704338B (en) | 2023-10-25 |
| RU2017128308A3 (fr) | 2019-10-24 |
| EP3245208A4 (fr) | 2018-10-17 |
| RU2017128308A (ru) | 2019-02-14 |
| JP2021035947A (ja) | 2021-03-04 |
| BR112017015206A2 (pt) | 2018-06-19 |
| WO2016115356A1 (fr) | 2016-07-21 |
| CN113816962A (zh) | 2021-12-21 |
| US20180009814A1 (en) | 2018-01-11 |
| CA2971460A1 (fr) | 2016-07-21 |
| AU2016206693A1 (en) | 2017-07-13 |
| MX366827B (es) | 2019-07-25 |
| US20240158400A1 (en) | 2024-05-16 |
| BR112017015206B1 (pt) | 2023-04-11 |
| US20220098200A1 (en) | 2022-03-31 |
| EP3245208A1 (fr) | 2017-11-22 |
| IL274716A (en) | 2020-07-30 |
| US20190367518A1 (en) | 2019-12-05 |
| US20200347064A1 (en) | 2020-11-05 |
| AU2020230323A1 (en) | 2020-10-01 |
| KR20170102887A (ko) | 2017-09-12 |
| MA41350A (fr) | 2017-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019008815A (es) | Sintesis de un inhibidor de tirosina quinasa de bruton. | |
| BR112015021995A2 (pt) | combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4 | |
| DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| PH12020552065A1 (en) | Ibrutinib combination therapy | |
| EA201690746A1 (ru) | Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии | |
| MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
| MX2021015368A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| WO2013010136A3 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MY187502A (en) | Salts of pi3k inhibitor and processes for their preparation | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| WO2016066726A3 (fr) | Acrylamides actifs | |
| IL284916A (en) | Cyclic molecules as Bruton's tyrosine kinase inhibitors | |
| BR112018076622A2 (pt) | pirrolo[2,3-d]piridazin-4-onas e pirazolo[3,4-d]piridazin-4-onas substituídas como inibidores de proteína cinase | |
| EP3966204A4 (fr) | 1-amino-1h-imidazole-5-carboxamide substitué utilisé en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| TW202419091A (zh) | 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物 | |
| EP4069689A4 (fr) | Imidazolecarboxamide substitué utilisé comme inhibiteurs de la tyrosine kinase de bruton | |
| UY35800A (es) | Combinaciones de inhibidores de la tirosina quinasa de bruton e inmunoterapias |